Anti-CD20 as the B cells targeting agent in the combined therapy to modulate anti-factor VIII immune responses in hemophilia A inhibitor mice

Neutralizing antibody formation against transgene products can represent a major complication following gene therapy with treatment of genetic diseases, such as hemophilia A. Although successful approaches have been developed to prevent the formation of anti-factor VIII (FVIII) antibodies, innovativ...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chao Lien eLiu, Peiqing eYe, Jacqueline eLin, Cherie L. Butts, Carol H Miao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2014-01-01
coleção:	Frontiers in Immunology
Assuntos:	Factor VIII Immunomodulation Hemophilia Anti-CD20 B cell depletion Tolerance induction
Acesso em linha:	http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00502/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!